SMis Pharmaceutical Nanotechnology: Applications & Commercialisation

Venue: Copthorne Tara Hotel

Location: London, United Kingdom

Event Date/Time: Jun 29, 2011 End Date/Time: Jun 30, 2011
Report as Spam


Nanotechnology may hold the key to a variety of issues faced by various therapeutic areas, this innovative area of pharmaceutical development therefore has the potential to make ground breaking advancements in areas such as RNAi and oncology. Click here for more information.

SMi’s is proud to present their Pharmaceutical Nanotechnology: Applications & Commercialisation conference taking place in London on June 29th and 30th, 2011. This event will explore the progression in this fascinating area and discuss the steps necessary to apply its virtues to current therapeutics and develop commercially successful products.

Key Presentations Include:

The business case for nanotechnology
Thomas Keller, Director, Open Innovation, GlaxoSmithKline

Miniaturisation and modelling of beads milling
Mostafa Nakach, Head of Pharmaceutical Engineering Group, Sanofi-Aventis R&D

Investigation of chitosan nanoparticle formulations
Michael Keller, Senior Fellow, siRNA Project Leader, Technical Research and Development (TRD), Novartis Pharma

Enabling oncology drug development with nanotechnology
Henry Havel, Senior Research Fellow, Product Research and Development, Eli Lilly and company

Industry partnering opportunities, open innovation, one solution
Peter Luke, Senior Director, R&D Business Development, Worldwide Business Development, Pfizer


Additional Information

ALSO FEATURING AN INTERACTIVE POST-CONFERENCE WORKSHOP ON: Nanomedicines: Regulatory Challenges and Opportunities Hosted by: Simon Holland, Director, Process Understanding & Control, GlaxoSmithKline Brian Kelly, Regulatory Lawyer, Covington & Burling LLP 1st July 2011, Copthorne Tara Hotel, London In association with: GlaxoSmithKline and Covington & Burling LLP